Anti-bag3 antibodies as therapeutic reagent in cardiovascular disease

Abstract

The present invention relates to the use of anti-BAG3 antibodies and its pharmaceutical formulation in the treatment of cardiovascular diseases.

1 . Anti-BAG3 antibody for use in the treatment of cardiovascular diseases. 
     
     
         2 . Anti-BAG3 antibody for use according to  claim 1 , characterised in that said cardiovascular diseases are selected from angina pectoris, pre-infarction angina, myocardial infarction, heart failure, ischemia, acute coronary disease, acute heart failure, chronic heart failure and iatrogenic heart disease. 
     
     
         3 . Anti-BAG3 antibody for use according to any one of the previous claims, characterised in that such antibody is a polyclonal or a monoclonal antibody. 
     
     
         4 . Anti-BAG3 antibody for use according to  claim 3 , characterised in that said monoclonal antibody is a murine antibody, a humanised antibody, a chimeric antibody, a recombinant antibody, a conjugated antibody, an scFv fragment (diabody, triabody and tetrabody), a Fab fragment or a F(ab′)2 fragment. 
     
     
         5 . Humanized anti-BAG3 antibody for use according to  claim 4 , characterised in that it comprises:
 a) a heavy chain amino acid sequence as encoded by SEQ ID N. 12 or at least the variable domain thereof or an amino acid sequence having a sequence identity of at least 80% thereof, and   b) a light chain amino acid sequence as encoded by SEQ ID N. 20 or at least the variable domain thereof or an amino acid sequence having a sequence identity of at least 80% thereof.   
     
     
         6 . Humanized anti-BAG3 antibody for use according to  claim 5 , characterized in that the heavy chain amino acid sequence as encoded by SEQ ID N. 12 or at least the variable domain thereof or an amino acid sequence having a sequence identity of at least 95% thereof, comprises the CDRs regions having the following amino acid composition: H-CDR1 comprises the amino acids GFNIKDTYMY (SEQ ID N. 5), H-CDR2 comprises the amino acids GVDPANGNTRYDPKFQG (SEQ ID N. 6), H-CDR3 comprises the amino acids DGAMDY (SEQ ID N. 7) and the light chain amino acid sequence as encoded by SEQ ID N. 20 or at least the variable domain thereof or an amino acid sequence having a sequence identity of at least 95% thereof, comprises the CDRs regions having the following amino acid composition: L-CDR1 comprises the amino acids KSSQSLLYSSNQKNYLA (SEQ ID N. 8), L-CDR2 comprises the amino acids WASTRES (SEQ ID N. 9) and L-CDR3 comprises the amino acids QQYYTYPLT (SEQ ID N. 10). 
     
     
         7 . Humanized anti-BAG3 antibody for use according  claim 5 , characterized in that said amino acid sequence having a sequence identity of at least 80% with respect to SEQ ID N. 12 is selected from SEQ ID N. 14, SEQ ID N. 16 or SEQ ID N. 18. 
     
     
         8 . Humanized anti-BAG3 antibody for use according  claim 5 , characterized in that said amino acid sequence having a sequence identity of at least 80% with respect to SEQ ID N. 20 is selected from SEQ ID N. 22, SEQ ID N. 24 or SEQ ID N. 26. 
     
     
         9 . Pharmaceutical composition comprising at least one anti-BAG3 antibody according to any one of the previous claims and at least one pharmaceutically acceptable excipient for use in the treatment of cardiovascular diseases, selected from angina pectoris, pre-infarction angina, myocardial infarction, heart failure, ischemia, acute coronary disease, acute heart failure, chronic heart failure and iatrogenic heart disease. 
     
     
         10 . Pharmaceutical composition for use according to  claim 9 , characterised in that said composition can be formulated in a form suitable for oral administration or in a form suitable for parenteral or topical administration. 
     
     
         11 . Pharmaceutical composition for use according to  claim 9 , characterised in that said form of oral administration can be selected from tablets, capsules, solutions, suspensions, granules, and oily capsules. 
     
     
         12 . Pharmaceutical composition for use according to  claim 9 , characterised in that said form of parenteral administration can be selected from intramuscular, intravenous, intradermal, subcutaneous, intraperitoneal, intranodal, or intrasplenic administration.